By all indications, it looks as if Idenix Pharmaceuticals Inc. has caught the eye of its new neighbor, Novartis Pharma AG, which is taking a controlling interest in Idenix and its viral drug programs through a deal that could be worth up to at least $862 million. (BioWorld Today)

By all indications, it looks as if Idenix Pharmaceuticals Inc. has caught the eye of its new neighbor, Novartis Pharma AG, which is taking a controlling interest in Idenix and its viral drug programs through a deal that could be worth up to at least $862 million. (BioWorld Today)

One hundred people have received notice of their layoffs from Transkaryotic Therapies Inc. as the company works to tighten its focus two months after receiving a negative FDA committee vote on its lead product, Replagal. (BioWorld Today)

One hundred people have received notice of their layoffs from Transkaryotic Therapies Inc. as the company works to tighten its focus two months after receiving a negative FDA committee vote on its lead product, Replagal. (BioWorld Today)